LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.17% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.16M.
Overvalued
The company’s latest PE is 2.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.68M shares, decreasing 4.88% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.04M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.